Guggenheim initiated coverage of GeneDx (WGS) with a Buy rating and $88 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Holdings: Positioned for Growth in Whole Genome Sequencing with Strong NICU Market Potential
- GeneDx management to meet with BTIG
- GeneDx Holdings: Strong Buy Rating Backed by Projected Growth and Competitive Edge
- GeneDx upgraded to Buy from Hold at Jefferies
- GeneDx price target lowered to $110 from $135 at TD Cowen